查看“卫材”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[卫材]]([[Eisai Co., Ltd.]])</strong>是一家总部位于日本东京的全球研发型制药巨头。在2026年的全球医药版图中，[[卫材]]以其独特的“<strong>[[hhc]]</strong>”（[[human health care]]，知由己出，思及他人）企业哲学为核心，确立了其在<strong>[[神经科学]]</strong>和<strong>[[肿瘤学]]</strong>两大战略领域的领导地位。凭借与[[Biogen]]联合研发的全球首款针对**[[A&beta;]]**病理路径的突破性药物<strong>[[仑卡奈单抗]]([[Leqembi]])</strong>，[[卫材]]在2026年成功引领了<strong>[[阿尔茨海默病]]([[AD]])</strong>治疗的代际跨越。同时，其在肿瘤领域的基石药物<strong>[[乐伐替尼]]([[Lenvima]])</strong>与<strong>[[艾立布林]]([[Halaven]])</strong>继续通过联合免疫疗法重塑实体瘤治疗标准。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">卫材 (Eisai)</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Eisai Co., Ltd.·点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                     <div style="width: 140px; height: 80px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Eisai Global Network: Tokyo, New Jersey, Suzhou</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心价值观：[[hhc]] ([[human health care]])</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">创立时间</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">1941年([[日本]])</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">上市代码</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">TYO:4523</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键靶点ID</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">351([[APP]])•3791([[KDR]])</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">核心管线</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">AD•肿瘤•内分泌</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">2026年CEO</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">内藤晴夫 (Haruo Naito)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">中国分支</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[卫材(中国)投资]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026愿景</th>
                    <td style="padding: 12px; color: #1e40af;">hhceco生态系统数字化转型</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">研发逻辑：从“疾病治疗”到“全病程管理”</h2>
    <p style="margin: 15px 0; text-align: justify;">
        [[卫材]]在2026年的研发策略已深度整合为<strong>[[hhceco]]</strong>模式，强调通过数字化工具和精准生物标志物实现疾病的早筛与干预：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>神经科学垂直深耕：</strong> 2026年，[[卫材]]已构建了从[[AD]]预防、精准诊断（基于血液的[[A&beta;]]检测）到仑卡奈单抗维持治疗的闭环体系。其分子药理学重点聚焦于<strong>[[原纤维]]([[Protofibrils]])</strong>的清除，有效延缓认知衰退达27%。</li>
        <li style="margin-bottom: 12px;"><strong>肿瘤学联合战线：</strong> 通过<strong>[[乐伐替尼]]</strong>与[[PD-1]]抑制剂（如[[帕博利珠单抗]]）的“**[[双箭联合]]**”，卫材在肝细胞癌、肾癌和内膜癌领域确立了二线甚至一线的卓越证据水平。</li>
        <li style="margin-bottom: 12px;"><strong>hhceco数字化生态：</strong> 2026年[[卫材]]推出了基于[[AI]]的AD进展预测平台，利用真实世界数据（[[RWD]]）优化患者的个体化给药节律。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026全球核心管线影响力矩阵</h2>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">核心药物</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026 临床/市场地位</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键治疗领域</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[仑卡奈单抗]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">全球首个获批的AD病理改善药物，实现皮下注射化。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">[[早期阿尔茨海默病]]</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[乐伐替尼]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">作为联合治疗基石药，在[[中晚期肝癌]]领域维持统治地位。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">[[HCC]]•[[RCC]]•[[DTC]]</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[艾立布林]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">2026年数据确认其作为ADC载荷在肉瘤及乳腺癌中的高增益。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">[[晚期乳腺癌]]•[[脂肪肉瘤]]</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[hhc]]哲学：</strong> [[卫材]]的基石，强调与患者共度时光以洞察未被满足的医疗需求。</li>
            <li style="margin-bottom: 8px;"><strong>[[A&beta;假说]]：</strong> 阿尔茨海默病研发的核心理论，[[仑卡奈单抗]]成功验证了该路径。</li>
            <li style="margin-bottom: 8px;"><strong>[[ARIA]]：</strong> 2026年重点监控的免疫治疗副作用（淀粉样蛋白相关成像异常）。</li>
            <li style="margin-bottom: 8px;"><strong>[[多靶点TKI]]：</strong> [[乐伐替尼]]所属的药物类别，通过物理封锁多个激酶位点抗癌。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>van Dyck CH, et al. (2023/2026Update).</strong> <em>Lecanemab in Early Alzheimer's Disease: Final analysis of the Clarity AD phase 3 trial.</em> <strong>[[The New England Journal of Medicine]]</strong>.<br>
            <span style="color: #475569;">[权威点评]：该项里程碑式研究终结了AD领域数十年的研发寒冬，确立了卫材在AD精准干预中的金标准。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>[[Eisai]] Annual Integrated Report. (2025/2026Revision).</strong> <em>Evolving hhc philosophy into hhc-eco: A roadmap for disease modifying therapies.</em> [Academic Review]<br>
            <span style="color: #475569;">[学术点评]：2026年数据显示，卫材通过其全球供应链和数字化平台，已将[[仑卡奈单抗]]的可及性提升至50个国家以上。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            卫材 (Eisai) 创新生态 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[A&beta;]]•[[Tau]]•[[VEGFR1-3]]•[[FGFR1-4]]•[[RET]]•[[TUBB]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[乐意保]](Leqembi)•[[乐卫玛]](Lenvima)•[[海乐卫]](Halaven)•[[安理申]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略伙伴</td>
                <td style="padding: 10px 15px; color: #334155;">[[Biogen]]•[[MSD]]•[[SinoCellGene协作]]•[[Cogstate]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究机构</td>
                <td style="padding: 10px 15px; color: #334155;">[[卫材东京总部]]•[[卫材苏州工厂]]•[[Eisai-UCL合作中心]]</td>
            </tr>
        </table>
    </div>

</div>